Cefiderocol for the Treatment of Adult and Pediatric Patients with Cystic Fibrosis and Achromobacter xylosoxidans Infections.

Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pre-treatment in vitro resistance was seen in 3/8 cases. Clinical response occurred after 11/12 treatment courses. However, microbiologic relapse was observed after 11/12 treatment courses, notably without emergence of resistance.

[1]  R. Wunderink,et al.  Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. , 2020, The Lancet. Infectious diseases.

[2]  R. Wunderink,et al.  Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. , 2020, The Lancet. Infectious diseases.

[3]  F. Forfori,et al.  Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-Negative infections in ICU patients. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  M. Brownstein,et al.  Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan‐drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient , 2020, Pediatric pulmonology.

[5]  S. Shelburne,et al.  Activity of Cefiderocol and Comparators against Isolates from Cancer Patients , 2020, Antimicrobial Agents and Chemotherapy.

[6]  J. Shimada,et al.  Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects , 2019, The Journal of antimicrobial chemotherapy.

[7]  M. Hackel,et al.  In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. , 2019, International journal of antimicrobial agents.

[8]  J. Karlowsky,et al.  Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli , 2019, Drugs.

[9]  K. Kazmierczak,et al.  In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). , 2019, International journal of antimicrobial agents.

[10]  R. Echols,et al.  Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. , 2018, The Lancet. Infectious diseases.

[11]  D. Fouts,et al.  ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases , 2018, Antimicrobial Agents and Chemotherapy.

[12]  T. Nishikawa,et al.  In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria , 2017, Antimicrobial Agents and Chemotherapy.

[13]  R. Sadikot,et al.  Achromobacter respiratory infections. , 2015, Annals of the American Thoracic Society.

[14]  A. Peleg,et al.  Stenotrophomonas, Achromobacter, and Nonmelioid Burkholderia Species: Antimicrobial Resistance and Therapeutic Strategies , 2015, Seminars in Respiratory and Critical Care Medicine.